SCHEMBL186408

SCHEMBL186408

[C]1=CC=CCC1=Cc1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.38
PIM3 Q86V86 1/20 0.38
PIM2 Q9P1W9 1/20 0.38
CYP1A2 P05177 3/20 0.34
HPGD P15428 1/20 0.33
F3 P13726 1/20 0.32
MEN1 O00255 1/20 0.32
NPC1 O15118 1/20 0.32
KMT2A Q03164 1/20 0.32
CA2 P00918 1/20 0.32
NAT1 P18440 1/20 0.32
EPHX1 P07099 1/20 0.32
ALDH1A1 P00352 2/20 0.32
HTT P42858 1/20 0.32
LMNA P02545 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
CYP2D6 P10635 1/20 0.31
MAPT P10636 1/20 0.31
CYP2C19 P33261 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9488876 0.68
SCHEMBL9209921 0.67 MEN1 (0.34) PIM1PIM3PIM2CYP1A2MEN1
SCHEMBL6745371 0.64 ALDH1A1 (0.37) PIM1PIM3PIM2CYP1A2HPGD
SCHEMBL6836753 0.61 AKT1 (0.42) CYP1A2HPGDF3MEN1KMT2A
Methylamine SCHEMBL28226585 0.61 ALDH1A1 (0.35) PIM1PIM3PIM2CYP1A2HPGD
SCHEMBL28066368 0.60 CYP1A2 (0.44) PIM1PIM3PIM2CYP1A2HPGD
SCHEMBL22471741 0.58 CYP1A2 (0.34) PIM1PIM3PIM2CYP1A2HPGD
SCHEMBL25400816 0.58 HPGD (0.48) CYP1A2HPGDF3MEN1KMT2A
SCHEMBL8466451 0.57 ALDH1A1 (0.32) ALDH1A1LMNA
SCHEMBL10632138 0.57 CYP1A2 (0.52) PIM1PIM3PIM2CYP1A2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140350035-A1 COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR- ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-27 US claimed
CN-103788321-A Short carbon chain fluorine polyurethane compound and water and oil repellent agent containing same JINTEX CORP 2014-05-14 CN claimed
EP-2555773-A1 COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4 INHIBITORS AND EP4 RECEPTOR ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2013-02-13 EP claimed
EP-2400962-A1 DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS Boehringer Ingelheim International GmbH (DE) 2012-01-04 EP claimed
EP-2400961-A1 DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS Boehringer Ingelheim International GmbH (DE) 2012-01-04 EP claimed
WO-2011124524-A1 COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4 INHIBITORS AND EP4 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-13 WO claimed
WO-2010097332-A1 DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 WO claimed
WO-2010097334-A1 DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 WO claimed
EP-2205609-A2 HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES Boehringer Ingelheim International GmbH (DE) 2010-07-14 EP claimed
WO-2009050242-A2 HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-04-23 WO claimed
US-5159074-A AMINOMETHANEPHOSPHONIC ACID ARYL ESTERS, A PROCESS FOR THEIR PRODUCTION AND THEIR USE BAYER AKTIENGESELLSCHAFT (DE) 1992-10-27 US claimed
EP-3068823-B1 FIBER-REINFORCED RESIN COMPOSITES AND METHODS OF MAKING THE SAME BOEING CO (US) 2019-07-24 EP disclosed
US-9012533-B2 Fiber-reinforced resin composites and methods of making the same THE BOEING COMPANY (US) 2015-04-21 US disclosed
US-20150080494-A1 Fiber-Reinforced Resin Composites and Methods of Making the Same THE BOEING COMPANY (US) 2015-03-19 US disclosed
US-20140350035-A1 COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR- ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-27 US disclosed
US-6268072-B1 AROMATIC RESIN EASTMAN KODAK COMPANY 2001-07-31 US disclosed
EP-1094101-A2 Electroluminescent devices having naphthylanthracene-based polymers EASTMAN KODAK COMPANY (US) 2001-04-25 EP disclosed
EP-1088875-A2 Electroluminescent devices having phenylanthracene-based polymers EASTMAN KODAK COMPANY (US) 2001-04-04 EP disclosed
CN-1112924-A Novel thiazine or thiomorpholine derivatives SANTEN PHARMACEUTICAL CO LTD (JP) 1995-12-06 CN disclosed
US-5159074-A AMINOMETHANEPHOSPHONIC ACID ARYL ESTERS, A PROCESS FOR THEIR PRODUCTION AND THEIR USE BAYER AKTIENGESELLSCHAFT (DE) 1992-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140350035-A1 COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR- ANTAGONISTS PTGER4, PTGER1, PDE4A PIM1 2955/4885PIM3 3119/4885PIM2 3022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.